These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21418179)

  • 21. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol.
    Becker ML; van Uden RCAE; Giezen TJ; Meijer K; Houtenbos I; van den Bemt PMLA
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1457-1464. PubMed ID: 32524154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
    Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
    Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial.
    Ageno W; Crowther M; Steidl L; Ultori C; Mera V; Dentali F; Squizzato A; Marchesi C; Venco A
    Thromb Haemost; 2002 Jul; 88(1):48-51. PubMed ID: 12152676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
    Visser LE; Bleumink GS; Trienekens PH; Vulto AG; Hofman A; Stricker BH
    Br J Haematol; 2004 Oct; 127(1):85-9. PubMed ID: 15384981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients.
    Montes R; Nantes O; Alonso A; Zozaya JM; Hermida J
    Br J Haematol; 2008 Dec; 143(5):727-33. PubMed ID: 18950464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential drug-drug interaction between proton pump inhibitors and warfarin.
    Henriksen DP; Stage TB; Hansen MR; Rasmussen L; Damkier P; Pottegård A
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1337-40. PubMed ID: 26395871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
    van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
    Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.
    Wey PF; Petitjeans F; Lions C; Ould-Ahmed M; Escarment J
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):173-7. PubMed ID: 18775393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.